Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542938 | 1.00 | MET (0.56) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL371889 | 0.90 | MET (0.60) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL371861 | 0.90 | MET (0.51) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL3544369 | 0.87 | MET (0.58) | METFLT3KDRAXL | |
| SCHEMBL5050761 | 0.86 | MET (0.58) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL10254472 | 0.84 | FLT3 (0.49) | METFLT3KDRPDGFRAAXL | |
| SCHEMBL371687 | 0.83 | MET (0.48) | METFLT3KDRPDGFRAEGFR | |
| SCHEMBL29487188 | 0.82 | PDGFRA (0.59) | METKDRPDGFRAAXL | |
| SCHEMBL174159 | 0.82 | PDGFRA (0.59) | METKDRPDGFRAAXL | |
| SCHEMBL20032551 | 0.82 | FLT3 (0.57) | METFLT3KDRPDGFRAAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732613-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007033196-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060613-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | MET 1/4885FLT3 91/4885KDR 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.